Search

Your search keyword '"Gandhi Damaj"' showing total 3 results
Start Over Author "Gandhi Damaj" Journal leukemia & lymphoma
3 results on '"Gandhi Damaj"'

2. End-of-treatment 18F-FDG PET/CT in diffuse large B cell lymphoma patients: ΔSUV outperforms Deauville score.

Author

Allioux, François, Gandhi, Damaj, Vilque, Jean-Pierre, Nganoa, Cathy, Gac, Anne-Claire, Aide, Nicolas, and Lasnon, Charline

Subjects
*B cell lymphoma, *DIFFUSE large B-cell lymphomas, *END of treatment, *REGRESSION analysis, *SURVIVAL analysis (Biometry)
Abstract

In DLBCL, the Deauville scoring system (DS) is the standard for PET/CT response assessment. An alternative system, based on the semi-quantitative change in standardized uptake values, namely ΔSUVmax, has been reported to be more objective than the DS. We aimed to compare ΔSUVmax and DS for risk stratification of DLBCL patients on end-of-treatment (EoT) PET. 108 consecutive patients were included. 2-year EFS Kaplan–Meier survival analyses and Cox regression models were performed. 2-year EFS was significantly different between favorable ΔSUVmax (favΔ < −86.5%) and unfavorable ΔSUVmax (unfavΔ ≥ −86.5%) patients: 100.0% ± 0.0 versus 58.3% ± 14.2 (p = 0.001). On Cox multivariable regression, ΔSUVmax status was the only independent predictor of 2-year EFS, outperforming DS. Therefore, ΔSUVmax should be computed for non-responder patients, especially DS4, as the 2-year EFS is not different between responders and non-responders in the case of favΔ. Further studies are needed in order to confirm this hypothesis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

3. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

Author

Pier Luigi Zinzani, Wolfram Brugger, Eckhart Weidmann, Eva Kimby, Gandhi Damaj, Bruce D. Cheson, Michinori Ogura, Brad S. Kahl, Clemens-Martin Wendtner, Martin Dreyling, Cheson, Bruce D, Brugger, Wolfram, Damaj, Gandhi, Dreyling, Martin, Kahl, Brad, Kimby, Eva, Ogura, Michinori, Weidmann, Eckhart, Wendtner, Clemens Martin, and Zinzani, PIER LUIGI

Subjects
Bendamustine, Cancer Research, medicine.medical_specialty, Consensus Development Conferences as Topic, Chronic lymphocytic leukemia, Drug Resistance, Reviews, Review, NHL, 03 medical and health sciences, 0302 clinical medicine, Hodgkin, Hematologic disorders, Recurrence, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Humans, Medicine, In patient, Dosing, Disease management (health), Intensive care medicine, Antineoplastic Agents, Alkylating, Multiple myeloma, business.industry, Disease Management, Hematology, medicine.disease, Hematologic Diseases, Lymphoma, multiple myeloma, Oncology, Hematologic Neoplasms, 030220 oncology & carcinogenesis, Retreatment, Immunology, Disease Progression, business, CLL, 030215 immunology, medicine.drug
Abstract

Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results